rs397515774
Variant summary
Our verdict is Pathogenic. Variant got 23 ACMG points: 23P and 0B. PS1PM1PM2PM5PP2PP3_StrongPP5_Very_Strong
The NM_000138.5(FBN1):c.2489G>C(p.Cys830Ser) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another nucleotide change resulting in same amino acid change has been previously reported as Likely pathogenicin ClinVar. Another variant affecting the same amino acid position, but resulting in a different missense (i.e. C830Y) has been classified as Pathogenic.
Frequency
Consequence
NM_000138.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 23 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
FBN1 | NM_000138.5 | c.2489G>C | p.Cys830Ser | missense_variant | 21/66 | ENST00000316623.10 | |
FBN1 | NM_001406716.1 | c.2489G>C | p.Cys830Ser | missense_variant | 20/65 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
FBN1 | ENST00000316623.10 | c.2489G>C | p.Cys830Ser | missense_variant | 21/66 | 1 | NM_000138.5 | P1 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Marfan syndrome Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Dec 21, 2012 | The c.2489G>C (p.Cys830Ser) has not been previously identified by our laboratory , but has been reported in the Korean Mutation Database (mutation ID KM0000769) in a patient with Marfan syndrome. In addition, the same amino acid change (p.Cy s830Ser) caused by a different DNA change (c.2488T>A) has been identified in one patient with clinical features of Marfan syndrome that met Ghent criteria (Sthe neur 2009). The variant identified in this individual has not been identified in large and broad populations by the NHLBI Exome Sequencing Project (http://evs.g s.washington.edu/EVS). Computational analyses (biochemical amino acid properties , conservation, AlignGVGD, PolyPhen2, and SIFT) suggest that the Cys830Ser varia nt may impact the normal function of the protein, though this information is not predictive enough to conclusively determine pathogenicity. In addition, this va riant affects a cysteine residue; cysteine substitutions are a common finding in individuals with Marfan syndrome (Schrijver 1999). In summary, this variant is likely pathogenic, though additional studies are required to fully establish its clinical significance. - |
Familial thoracic aortic aneurysm and aortic dissection Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Feb 14, 2022 | The p.C830S variant (also known as c.2489G>C), located in coding exon 20 of the FBN1 gene, results from a G to C substitution at nucleotide position 2489. The cysteine at codon 830 is replaced by serine, an amino acid with dissimilar properties. The majority of FBN1 mutations identified to date have involved the substitution or generation of cysteine residues within cbEGF domains (Vollbrandt T et al. J Biol Chem. 2004;279(31):32924-32931). This alteration has been reported in an individual with a clinical diagnosis of Marfan syndrome (Baudhuin LM et al. J Hum Genet, 2015 May;60:241-52). In addition, a different alteration located at the same position, resulting in the same protein change, p.C830S (c.2488T>A), has been detected in an individual reported to have classical Marfan syndrome (Stheneur C et al. Eur J Hum Genet, 2009 Sep;17:1121-8). Based on internal structural assessment, this alteration eliminates a structurally critical disulfide bond in the structurally sensitive cbEGF domain #09. This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic. - |
Marfan syndrome;C4707243:Familial thoracic aortic aneurysm and aortic dissection Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 07, 2023 | This sequence change replaces cysteine, which is neutral and slightly polar, with serine, which is neutral and polar, at codon 830 of the FBN1 protein (p.Cys830Ser). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with Marfan syndrome (Invitae). ClinVar contains an entry for this variant (Variation ID: 42310). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt FBN1 protein function with a positive predictive value of 95%. This variant affects a cysteine residue in the EGF-like, TGFBP or hybrid motif domains of FBN1. Cysteine residues are believed to be involved in intramolecular disulfide bridges and have been shown to be important for FBN1 protein structure (PMID: 16905551, 19349279). In addition, missense substitutions affecting cysteine residues within these domains are significantly overrepresented among patients with Marfan syndrome (PMID: 16571647, 17701892). For these reasons, this variant has been classified as Pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at